Abstract OBJECTIVE: To study the clinical and biological characteristics and prognosis of t(8;21)/AML1-ETO-positive childhood acute myeloid leukemia (AML). METHODS: The clinical data of 55 children who were diagnosed as t (8; 21)/AML1-ETO-positive AML were retrospectively studied. Event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) rates were estimated by the Kaplan-Meier method. Prognostic factors were evaluated by COX regression analysis software. RESULTS: Of the 55 patients, 4 patients gave up treatment after the diagnosis was confirmed and 4 patients were lost to follow-up after the first chemotherapy course. The remaining 47 patients received a double-induction therapy. The total complete remission (CR) rate was 71% and 94% after the first and second chemotherapy course, respectively. The disease was relapsed in 10 patients (21%). The 5-year EFS, DFS and OS rates were (56.1±7.9)%, (59.8±8.1)%, and (72.0±8.1)%, respectively. Multivariate analysis showed that age was an independent risk factor for the long-term prognosis. The older children had a greater risk of experiencing an accident or death (P<0.05).The 5-year OS rate in 27 patients with regular consolidation chemotherapy was significantly higher than 13 patients with irregular chemotherapy after CR ［(47.5±17.1)% vs (38.9±17.3)%; P<0.01］. CONCLUSIONS: Childhood t(8;21)/AML1-ETO-positive AML is a highly heterogeneous disease, with a high CR rate and a good long-term prognosis. Age is one of the important factors affecting the long-term therapeutic effect. Regular consolidation chemotherapy applied after CR usually is helpful.
WU Jun,ZHANG Le-Ping,LU Ai-Dong et al. Clinical features and prognosis of t (8; 21)/AML1-ETO-positive childhood acute myeloid leukemia[J]. 中国当代儿科杂志, 2011, 13(12): 931-935.
WU Jun,ZHANG Le-Ping,LU Ai-Dong et al. Clinical features and prognosis of t (8; 21)/AML1-ETO-positive childhood acute myeloid leukemia[J]. CJCP, 2011, 13(12): 931-935.
［1］Kwong YL, Ching LM, Liu HW, Lee CP, Pollock A, Chan LC. 8;21 translocation and multilineage involvement［J］. Am J Hematol, 1993, 43(3): 212-216.
［2］Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000［J］. Leukemia, 2005, 19(12): 2101-2116.
［3］Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y,et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report［J］. Leukemia, 2005, 19(12): 2072-2081.
［8］Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr, Kalwinsky DK, et al. Distinctive immunophenotypic features of t(8;21) (q22;q22) acute myeloblastic leukemia in children［J］. Blood, 1992, 80（12）: 3182-3188.
［10］von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98［J］. J Clin Oncol, 2010, 28 (16): 2682-2689.
［11］Abdel Rahman H, Farrag SA, El-Attar IA. AML1/ETO fusion gene in de novo pediatric acute myeloid leukemia: clinical significance and prognostic implications［J］. J Egypt Natl Canc Inst, 2007, 19(1):39-47.
［12］Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Long-term results in children with AML: NOPHO-AML Study Group: report of three consecutive trials［J］. Leukemia, 2005, 19(12): 2090-2100.
［13］Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)［J］. Eur J Haematol, 2007, 78(6): 468-476.
［14］Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children Cancer Group［J］. Blood, 2001, 97(1): 56-62.
［15］Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era［J］. Leukemia, 2005, 19(6): 965-970.
